The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.

Yun-Song YangYi-Xing RenCheng-Lin LiuShuang HaoXiao-En XuXi JinYi-Zhou JiangZhi-Ming Shao

Published in: Breast cancer research and treatment (2022)

Our 7-mRNA signature could accurately predict recurrence risks of early-stage TNBCs. This model may facilitate personalized therapy decision-making for early-stage TNBCs individuals.

Keyphrases

early stage
decision making
sentinel lymph node
single cell
squamous cell carcinoma
human health
risk assessment
radiation therapy
climate change
binding protein
lymph node
smoking cessation